Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound ...
Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with ...
Fresenius Kabi voluntarily recalled one lot of morphine sulfate injection due to a labeling mix-up with prefilled syringes of the opioid dilaudid that could trigger an overdose resulting in severe ...
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine. | Despite a major curveball thrown by the ...
Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting ...
In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups. | In a remarkable turnaround, ...
After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...
Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing ...
News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results